Cancer treatment has undergone remarkable advances, with immunotherapy standing out as one of the most transformative approaches. By activating the body’s own immune system to recognize and destroy tumor cells, immunotherapy has changed outcomes for many patients. However, a significant proportion of individuals either fail to respond or eventually develop resistance to these therapies. This challenge has driven researchers to look beyond traditional oncologic targets and explore how seemingly distant biological factors, such as the gut microbiota, can profoundly influence treatment success.

One strategy that has gained growing attention is fecal microbiota transplantation (FMT), a procedure in which fecal material from a healthy donor is transferred into the intestinal tract of a patient to restore or reshape the gut microbiome. Originally developed to treat recurrent Clostridioides difficile infections that respond poorly to conventional antibiotics, FMT has proven highly effective in that setting. Its success has paved the way for exploration in other fields, including cancer immunotherapy.

 

The Role of the Gut Microbiome in Immunotherapy

The gut microbiota refers to the complex community of bacteria, viruses, fungi, and other microorganisms that reside in the intestine. These organisms are not only essential for digestion but also play a central role in regulating immune function. Growing evidence shows that the composition of the gut microbiota can significantly influence how the immune system responds to cancer therapies, particularly immune checkpoint inhibitors targeting PD-1, PD-L1, or CTLA-4.

A scientific review published in the Journal of Hematology & Oncology demonstrated that specific microbial communities can enhance antitumor immunity by increasing the activation and infiltration of key immune cells, such as CD8+ cytotoxic T cells and dendritic cells. These cells are critical for recognizing tumor antigens and mounting an effective immune response. In contrast, microbial imbalance (or dysbiosis) has been associated with an increase in immunosuppressive populations, including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), which can blunt the effectiveness of immunotherapy.

These findings suggest that favorably modifying a patient’s gut microbiota, through FMT or other interventions, may help recalibrate immune responses and enhance the therapeutic impact of cancer immunotherapy.

 

Clinical Evidence: Improved Immunotherapy Responses With FMT 

 

Overcoming Immunotherapy Resistance in Gastrointestinal Cancers

A small but influential study published in Cell Host & Microbe in 2024 evaluated patients with gastrointestinal cancers who had developed resistance to immune checkpoint inhibitors. Some participants received fecal microbiota transplants from donors who had previously responded well to immunotherapy. The results were striking: more than half of the treated patients demonstrated a meaningful improvement in their response to immunotherapy following FMT. Importantly, the researchers identified specific bacterial strains that were associated with improved immune activity and tumor control.

This clinical evidence reinforces the concept that the gut microbiota is not merely a passive bystander but an active regulator of how patients respond to immune-based cancer treatments. Certain beneficial bacteria appear capable of shifting the immune environment toward an antitumor state rather than an immunosuppressive one.

 

Enhancing Responses in Melanoma and Other Solid Tumors

Earlier clinical findings, including studies supported by the U.S. National Cancer Institute (NCI), have reported similar outcomes in patients with advanced melanoma. Individuals who initially failed to respond to immune checkpoint inhibitors achieved renewed therapeutic responses after receiving FMT from donors who had responded successfully to immunotherapy.

These results suggest that altering the gut microbial composition can, in effect, “reprogram” the immune system or tumor microenvironment, restoring the immune system’s ability to recognize and attack cancer cells. Additional studies have shown that FMT is generally safe and well tolerated in these settings, supporting its continued evaluation in larger clinical trials.

 

Why Does the Microbiome Influence Treatment Response?

Although the precise mechanisms are still under investigation, several key biological processes help explain how the gut microbiome shapes immunotherapy outcomes.

 

Immune Modulation

Gut microbes influence the function of antigen-presenting cells, such as dendritic cells, as well as effector T cells. This interaction can enhance tumor antigen presentation and promote stronger, more sustained antitumor immune responses.

 

Microbial Metabolites

Intestinal microorganisms produce a wide range of metabolites, including short-chain fatty acids and other bioactive compounds, that have immunomodulatory effects. These metabolites can influence cytokine production, systemic inflammation, and immune cell differentiation, creating conditions that support effective immunotherapy.

 

Microbial Diversity and Balance

Higher microbial diversity is generally associated with better immune resilience and improved treatment responses. FMT from immunotherapy-responsive donors may help restore microbial diversity and functional balance in patients with dysbiosis, improving immune competence.

 

Figure 1. The interaction between the gut microbiome and the immune system and its role in modulating cancer immunotherapy responses. The illustration highlights how microbial composition influences immune activation, treatment effectiveness, and resistance mechanisms.

 

Safety Considerations and Potential Risks

Despite its promise, FMT is not without risks. The transfer of fecal material carries the theoretical risk of transmitting pathogens or unwanted microorganisms if donor screening and processing protocols are not rigorously followed. For this reason, FMT must be performed in carefully controlled clinical settings with strict donor selection, screening, and monitoring procedures.

Additionally, while early clinical trials have yielded encouraging results, most studies to date have involved relatively small patient populations.

 

The Future of Integrated Medicine: Microbiome and Immunotherapy

The integration of microbiome science into oncology represents one of the most exciting frontiers in precision medicine. Beyond fecal transplants, researchers are actively exploring alternative strategies to modulate the gut microbiota, including:

 

• Targeted dietary interventions and probiotics designed to support bacteria linked to favorable immune responses
• Prebiotic and postbiotic supplements that influence microbial function rather than microbial composition alone
• Identification of microbial biomarkers that predict which patients are most likely to benefit from immunotherapy

 

These approaches aim not only to improve treatment effectiveness but also to reduce side effects, expand access to advanced therapies, and personalize cancer care based on each patient’s unique biological profile.

 

Conclusion

Research into fecal microbiota transplantation and its ability to enhance cancer immunotherapy is rapidly evolving. Emerging clinical evidence suggests that FMT can improve therapeutic responses in patients who were previously resistant to immunotherapy, across multiple cancer types including gastrointestinal malignancies and melanoma.

Beyond introducing a new therapeutic tool, this research highlights a broader paradigm shift: viewing the human body as an integrated ecosystem in which host biology and the microbiome work together to shape disease outcomes. As larger clinical trials are conducted and our understanding deepens, microbiome-based interventions—including FMT—may become a standard component of precision oncology, offering new hope for patients facing limited treatment options.

 

Main reference: 

Porcari, S., Ciccarese, C., Heidrich, V., Rondinella, D., Quaranta, G., Severino, A., Arduini, D., Buti, S., Fornarini, G., Primi, F., Stumbo, L., Giannarelli, D., Giudice, G. C., Damassi, A., Giron Berríos, J. R., Punčochář, M., Barbazuk, T. B., Piccinno, G., Pinto, F., … Ianiro, G. (2026). Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial. Nature Medicine, 1–9. https://doi.org/10.1038/s41591-025-04189-2 

 

Other references: 

Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., Vynnychenko, I., Kryzhanivska, A., Bondarenko, I., Azevedo, S. J., Borchiellini, D., Szczylik, C., Markus, M., McDermott, R. S., Bedke, J., Tartas, S., … KEYNOTE-426 Investigators (2019). Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England journal of medicine, 380(12), 1116–1127. https://doi.org/10.1056/NEJMoa1816714 

Gunjur, A., Shao, Y., Rozday, T., Klein, O., Mu, A., Haak, B. W., Markman, B., Kee, D., Carlino, M. S., Underhill, C., Frentzas, S., Michael, M., Gao, B., Palmer, J., Cebon, J., Behren, A., Adams, D. J., & Lawley, T. D. (2024). A gut microbial signature for combination immune checkpoint blockade across cancer types. Nature medicine, 30(3), 797–809. https://doi.org/10.1038/s41591-024-02823-z 

Ianiro, G., Tilg, H., & Gasbarrini, A. (2016). Antibiotics as deep modulators of gut microbiota: between good and evil. Gut, 65(11), 1906–1915. https://doi.org/10.1136/gutjnl-2016-312297